Burning Rock Dx
Burning Rock Dx is recorded as a service provider in 16 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 16 of 16 trials · Latest update first
(22615 SOHO-02) A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations
Sponsor Bayer AG
- Start (EU)
- Latest update
- Estimated end
(Peak) A Phase 3 Randomized, Open-label, Multicenter Clinical Study of CGT9486+Sunitinib vs Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors
Sponsor Cogent Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl‑2 Inhibitor BGB‑11417 in Patients With Myeloid Malignancies
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
Full title of the clinical trial: A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB 3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
An Open Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB 11417) as Monotherapy and in Combination with Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
An International, Phase 3, Open-label, Randomized Study of Zanubrutinib (BGB-3111) Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Open-label Study to Investigate the Safety of Sonrotoclax Ramp-up Schedule(s) in Adult Patients With Hematological Malignancies
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with First-Line Osimertinib Treatment and whose Tumors harbor a C797S mutation within the Epidermal Growth Factor Receptor Gene
Sponsor Wayshine Biopharm Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
Randomized, Controlled, Open-label, Phase 3, Global Multi-Center Trial to Assess the Efficacy and Safety of Zipalertinib plus Chemotherapy versus Chemotherapy alone, in Patients with Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Sponsor Taiho Oncology Inc.
- Start (EU)
- Latest update
- Estimated end
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 with Tislelizumab in Patients with Advanced Solid Tumors
Sponsor Beigene Ltd.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Burning Rock Dx?
The 2026-10-09 snapshot links Burning Rock Dx to 16 distinct CTIS trials. Recorded services include Laboratory services, storage of Future Research samples, biomarker sample storage, Biomarker sample storage, among 7 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Burning Rock Dx?
The most frequently recorded therapeutic areas are Haematological Malignancies, Solid Tumor Oncology, Gastroenterology, Respiratory. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Burning Rock Dx conducted?
The linked trials record locations in 20 countries, including France, Italy, Spain, Poland, Germany. These are trial locations, not confirmed office locations or countries where Burning Rock Dx delivered services.
What can this page tell me about Burning Rock Dx's trial experience?
Browse 16 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Burning Rock Dx. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Burning Rock Dx LLC